Lupin aimed to boost market growth with 100% share capital of VISUfarma

Image Credit: MSN

Announcement

Lupin peaked with 1.62% to 1951.90 after the company, Nanomi B.V., had fixed a deal with a definitive agreement for acquiring 100% stake in VISUfarma B.V. at an enterprise value worth $190 million. The VISUfarma B.V. is a portfolio company of a popular healthcare specialist investor, GHO Capital Partners LLP (GHO). The stake of VISUfarma with its wide range of portfolio of creative eye health products and developed commercial infrastructure, well connects with Lupin’s smart strategy to extend its European business and impact to promote it as an advancement of the company’s worldwide specialty franchise. By adding VISUfarmas, developed commercial operations, Lupin will dive into the impressive ophthalmology market.

The market has witnessed prominent worldwide growth fuelled by an aging population globally and the rising incidence of diabetes-based eye complications. Including the rising awareness of preventive care. The expansion into Europe is an opportunity for Lupin to capitalize on the expansion development and VISUfarma to highlight its potency to marketize and drive business growth in the huge healthcare spectrum. The smart strategy of Lupin has led to the growth of the company’s financial terms and has built a strong position in the pharmaceutical market globally.

Vice versa, benefit to VISUfarma and Lupin

VISUfarma’s developed European operations will offer direct appearance, business diversification, and market expansion opportunities throughout the key European countries, including the UK, Spain, France, Germany, and Italy. Additionally, VISUfarma's vast 60+ branded ophthalmology products portfolio will unlock recent growth opportunities to leverage Lupin’s expansion strategy into the specialty segment throughout the regions. Alongside, it has the potential to fuel growth and development in Europe equally as in other sectors.

With this acquisition, Lupin will provide an entire portfolio of products in the space of glaucoma, eyelid hygiene, retinal health, dry eye, blepharitis, and targeted nutraceuticals prescribed by ophthalmologists. Lupin will smartly finance the acquisition with its existing cash amount on the balance sheet. The transaction is expected to close by the year ending 2025, attached to a few closing conditions.

The CEO of Lupin, Vinita Gupta, said, “We’re excited to welcome VISUfarma into the Lupin extended family. This acquisition powers up our dedication to provide innovative medicines to the communities and patients we serve. Apart from being additive, it also expands our presence in Europe and further forms our specialty franchise in ophthalmology.”